VVUS: VIVUS INC. (NASDAQ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: VLAD who wrote (19306)	3/8/1999 10:00:00 AM
From: RT	Read Replies (1) of 23519

VLAD, <<March 8, 1999 09:04 AM MOUNTAIN VIEW, Calif.--(BW HealthWire)--March 8, 1999--VIVUS, Inc. VVUS has been issued patent no. 5877216 for the "Treatment of Female Sexual Dysfunction" by the U.S. Patent Office. >> Was this the exciting news which prompted your recent enthusiasm to purchase more VVUS shares? Does this mean that every company that intends to market a cream for female erectile dysfunction must now PAY Vivus a royalty to distribute their products. This sounds like a serious blow to HVSF (Harvard Scientific) which was experimenting with female rabbits. Does this patent cover ED for female rabbits as well as humans? <gg>> RT

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next